跳至主要内容
临床试验/NCT03479320
NCT03479320已完成4 期

Efficacy of Perioperative Intravenous Lidocaine Infusion on Postoperative Analgesia in Patients Undergoing Oral and Maxillofacial Surgeries Under General Anesthesia

B.P. Koirala Institute of Health Sciences1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2018年3月28日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
40
试验地点
1
主要终点
Postoperative Numeric Rating Scale(NRS)

研究概览

简要总结

This will be a randomized double blinded clinical study conducted in patients undergoing oral and maxillofacial surgery under general anesthesia. Lidocaine group will receive intravenous bolus 1.5 mg/kg at induction followed by continuous infusion of 2 mg/kg/hr until the completion of surgery.Normal saline group will receive same amount of intravenous normal saline .The primary outcome will be postoperative pain using the NRS scale during first 24 hours and time to first analgesic request

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patients 18-60 years of age
  • Patients of ASA (American Society of Anesthesiologists) Class I or Class II (I- healthy with no systemic disease, II- mild systemic disease with no functional limitation) who require oral and maxillofacial surgeries under general anesthesia

排除标准

  • Refusal to give consent.
  • Hypersensitivity or allergy to the study medication.
  • ASA physical status III or more.
  • Subjects with known severe hepatic or renal dysfunction or cardiac dysrhythmia or atrioventricular block.
  • History of taking opioids or antiarrhythmic drugs within 1 week of surgery.
  • History of drug or alcohol abuse
  • History of psychiatric disorders.
  • Patients requiring emergency surgery.
  • Patients unable to comprehend pain assessment

研究组 & 干预措施

Lidocaine group

Experimental

Lidocaine group will receive intravenous bolus 1.5 mg/kg at induction followed by continuous infusion of 2 mg/kg/hr until the completion of surgery

干预措施: Lidocaine (Drug)

Placebo

Placebo Comparator

They will receive the same volume of 0.9% of normal saline as calculated for the experimental group

干预措施: Placebo (Drug)

结局指标

主要结局

Postoperative Numeric Rating Scale(NRS)

时间窗: 24 hours

Pain at rest and with cough or movement using the NRS scale, which ranges from 0 to 10; where 0 refers to no pain and 10 refers to most severe pain

次要结局

  • Total opioid consumption(24 hours)
  • Time to first analgesic request(24 hours)
  • Side effects(24 hours)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr Vivek Kumar Mahato

Post graduate resident in Department of Oral and Maxillofacial Surgery

B.P. Koirala Institute of Health Sciences

研究点 (1)

Loading locations...

相似试验

Usefulness of Lidocaine in Oral and Maxillofacial... | 临床试验